PubRank

Brian J Lopresti

Author PubWeight™ 77.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004 21.56
2 Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008 7.95
3 Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005 6.25
4 Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008 5.89
5 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007 3.91
6 Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005 2.17
7 The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006 2.10
8 Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. Am J Pathol 2008 1.68
9 Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006 1.65
10 Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: A pilot study. Acta Neurobiol Exp (Wars) 2010 1.46
11 Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods 2008 1.46
12 Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 2004 1.35
13 Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 2008 1.30
14 Molecular imaging of microglia/macrophages in the brain. Glia 2012 1.29
15 Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007 1.19
16 In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol 2013 1.17
17 PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. J Clin Invest 2004 1.15
18 Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009 1.14
19 The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: implications for PET imaging. Exp Neurol 2007 1.12
20 A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. J Neurochem 2007 1.12
21 A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010 1.11
22 Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med 2012 1.09
23 Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006 1.07
24 Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol 2006 1.07
25 PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 2008 1.00
26 Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies. Synapse 2009 0.97
27 In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 2011 0.93
28 Imaging of dopamine D2/3 agonist binding in cocaine dependence: a [11C]NPA positron emission tomography study. Synapse 2011 0.86
29 Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. Am J Nucl Med Mol Imaging 2013 0.82
30 Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET. J Nucl Med 2009 0.82
31 Altered cerebellar and prefrontal cortex function in rhesus monkeys that previously self-administered cocaine. Psychopharmacology (Berl) 2014 0.78
32 In vivo imaging in an ABSL-3 regional biocontainment laboratory. Pathog Dis 2014 0.77
33 Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ). Mol Imaging Biol 2012 0.77